Momentum Is Strong For Zai Lab Limited (NASDAQ: ZLAB)

After Hours

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Zai Lab Limited (ZLAB) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$5.39, or -12.57%, to $37.5. Volume reached 284 shares, with price reaching a high of $37.33 and a low of $37.33. Earlier, Yahoo Finance discussed this stock as it revealed Zai Lab to Present Analysis of the Impact of Timing for ZEJULA® (niraparib) Maintenance Treatment in Newly Diagnosed Advanced Ovarian Cancer at the 2022 International Gynecologic Cancer Society Meeting.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now.

Sponsored

Stocks Info

This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $37.33 and fluctuated between $43.02 as its day high and $36.67 as its day low. The current market capitalization of Zai Lab Limited is $3.81B. A total of 1.01 million shares were traded on the day, compared to an average of 559.24K shares.

In the most recent transaction, DIEKMAN JOHN D sold 1,000 shares of ZLAB for 50.17 per share on Feb 04. After the transaction, the Director now owns 67,615 company shares. In a previous transaction on Jan 20, Lis William sold 1,926 shares at 53.40 per share. ZLAB shares that Director owns now total 34,114.

Among the insiders who bought shares, WIRTH PETER acquired of 4,000 shares on Dec 08 at a per-share price of $71.36. This resulted in the Director holding 342,852 shares of ZLAB after the transaction. In another insider transaction, DIEKMAN JOHN D sold 1,000 shares at $91.65 per share on Nov 05. Company shares held by the Director now total 60,852.

Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for ZLAB in the last 3 months, the mean price target is $87.82 with high estimates of $199.00 and low estimates of $37.56. In terms of 52-week highs and lows, ZLAB has a high of $123.34 and a low of $22.51.

As of this writing, ZLAB has an earnings estimate of $-1.2 per share for the current quarter. EPS was calculated based on a consensus of 3 estimates, with a high estimate of $-0.97 per share and a lower estimate of $-1.46. The company reported an EPS of $-1.44 in the last quarter, which was -51.58% lower than expectations of $-0.95.

Balance Sheet Annually/Quarterly

In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 17 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ZLAB is Underweight with a score of 4.71. A total of 16 analysts rated the stock as Buy while 0 rated it as Overweight while 1 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

The 5 Best Inflation Stocks for 2022

292
294

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.